Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 1.16

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12

Sublingual apomorphine and Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 0.84

Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons Dis (2012) 0.83

A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol (2004) 0.81

Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase. Proc Natl Acad Sci U S A (1977) 0.80

Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1995) 0.78

Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? J Psychiatry Neurosci (2001) 0.77

L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation. Proc Natl Acad Sci U S A (1977) 0.77

Regiospecific synthesis of isoapocodeine from 10,11-dimethoxyaporphine by using Cunninghamella elegans. Appl Environ Microbiol (1978) 0.75

Editorial: Alternatives to levodopa. Br Med J (1976) 0.75

Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. J Neurol Neurosurg Psychiatry (1977) 0.75

Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med (1969) 6.16

Aromatic amino acids and modification of parkinsonism. N Engl J Med (1967) 5.46

Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med (1970) 2.25

Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology (1967) 1.71

Postural and action myoclonus in patients with parkinsonian type multiple system atrophy. Mov Disord (2000) 1.49

Meige disease: striatal dopaminergic preponderance. Neurology (1979) 1.46

Reaction time and acoustic startle in normal human subjects. Neurosci Lett (1995) 1.45

Essential tremor: treatment with propranolol. Neurology (1975) 1.38

Role of liver in regulating distribution and excretion of manganese. Am J Physiol (1966) 1.35

Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol (1972) 1.31

Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med (1975) 1.31

Chronic manganese poisoning. Clearance of tissue manganese concentrations with persistance of the neurological picture. Neurology (1968) 1.25

Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med (1970) 1.23

Levodopa, fertility, and longevity. Science (1977) 1.19

Chronic manganese poisoning. Individual susceptibility and absorption of iron. Neurology (1969) 1.17

L-dopa in parkinson's syndrome. N Engl J Med (1969) 1.17

Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. Brain (2005) 1.16

Blink reflex excitability cycle in hemifacial spasm. Neurology (1989) 1.11

L-Dopa for Parkinsonism. N Engl J Med (1968) 1.09

Clinical features of Meige's disease (idiopathic orofacial dystonia): a report of 17 cases. Arch Neurol (1981) 1.08

Parkinsonism and basal ganglia infarcts. Neurology (1984) 1.05

Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology (1975) 1.05

Prolongation of the life-span in mice adapted to large amounts of L-dopa. Proc Natl Acad Sci U S A (1974) 1.04

Interdependence of routes excreting manganese. Am J Physiol (1966) 1.03

Dependence of manganese turnover on intake. Am J Physiol (1966) 1.03

Experimental treatment of parkinsonism with L-Dopa. Neurology (1968) 0.99

Metabolic modification of Parkinson's disease and of chronic manganese poisoning. Annu Rev Med (1971) 0.99

Control of tissue manganese: initial absence and sudden emergence of excretion in the neonatal mouse. Am J Physiol (1975) 0.98

Parkinsonism and DOPA. Trans Assoc Am Physicians (1968) 0.95

Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci (2000) 0.94

Diets affecting treatment of parkinsonism with levodopa. J Am Diet Assoc (1973) 0.93

Myotatic reflexes and the on-off effect in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1981) 0.93

A mutation influencing the transportation of manganese, L-dopa, and L-tryptophan. Science (1972) 0.93

Vibration-induced presynaptic inhibition of the soleus H reflex is temporarily reduced by cortical magnetic stimulation in human subjects. Neurosci Lett (1994) 0.92

Melatonin and abnormal movements induced by L-dopa in mice. Science (1971) 0.90

Neurophysiological observations on the effects of botulinum toxin treatment in patients with dystonic blepharospasm. J Neurol Neurosurg Psychiatry (1991) 0.89

Responses of the soleus muscle to transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol (1994) 0.88

Autoimmunity in patients treated with levodopa. JAMA (1969) 0.87

The discrimination between magnesium and manganese by serum proteins. J Gen Physiol (1967) 0.87

Neurophysiological investigations in patients with head tremor. Mov Disord (1997) 0.87

Rotatory behavior induced by glycine injected into the substantia nigra of the rat. Exp Neurol (1976) 0.86

Apomorphine in Huntington's chorea: clinical observations and theoretical considerations. Life Sci (1974) 0.86

Metabolic modification of some neurologic disorders. JAMA (1969) 0.86

Blocking the negative effects of pyridoxine on patients receiving levodopa. JAMA (1971) 0.86

Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord (1995) 0.85

Changing the actions of neuroactive drugs by changing brain protein synthesis. Proc Natl Acad Sci U S A (1974) 0.85

Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms. Neurology (1979) 0.84

Manganese, melanins and the extrapyramidal system. J Neurosurg (1966) 0.83

Modification of the actions of some neuroactive drugs by growth hormone. Arch Neurol (1976) 0.83

Parkinsonism and levodopa. Clin Pharmacol Ther (1971) 0.83

Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats. J Neurosurg (1975) 0.83

Block of cerebral actions of L-dopa with methyl receptor substances. Nature (1971) 0.83

Diphenylhydantoin. Blocking of levodopa effects. Arch Neurol (1975) 0.83

Interactions between manganese and brain dopamine. Med Clin North Am (1976) 0.83

Levodopa, manganese, and degenerations of the brain. Harvey Lect (1974) 0.82

Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med (1972) 0.82

Melatonin and parkinsonism. JAMA (1972) 0.82

Meiges disease: a clinical form of facial convulsion, bilateral and medial. Arch Neurol (1979) 0.82

The 'geste antagonistique' induces transient modulation of the blink reflex in human patients with blepharospasm. Neurosci Lett (1998) 0.82

Functional interactions between biogenic amines, 3',5'-cyclic AMP and manganese. Nature (1968) 0.82

Recurrent hypersomnia in two adolescent males with Asperger's syndrome. J Am Acad Child Adolesc Psychiatry (1992) 0.81

Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N,N-dialkylated dopamines. J Med Chem (1975) 0.81

Effects of inhibitors and stimulators of protein synthesis on the cerebral actions of L-dopa. Neurosci Res (N Y) (1973) 0.81

Neutron activation analysis: the stability of manganese concentrations in human blood and serum. J Lab Clin Med (1966) 0.80

Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase. Proc Natl Acad Sci U S A (1977) 0.80

Levodopa in the treatment of Parkinsonism. JAMA (1971) 0.80

Magnetic resonance imaging in patients with concurrent Tourette's disorder and Asperger's syndrome. J Am Acad Child Adolesc Psychiatry (1993) 0.80

Letter: Somatostatin, growth hormone and parkinsonism. N Engl J Med (1976) 0.79

Oxybate sodium for parkinsonism. JAMA (1973) 0.78

Unexpected findings with apomorphine and their possible consequences. Adv Neurol (1974) 0.78

Quantitative correlation of dopamine-dependent adenylate cyclase with responses to levodopa in various mice. Proc Natl Acad Sci U S A (1977) 0.78

Normal proprioceptive trigeminal afferents in patients with Sjögren's syndrome and sensory neuronopathy. Ann Neurol (1990) 0.78

Slow turnover of manganese in active rheumatoid arthritis accelerated by prednisone. J Clin Invest (1968) 0.78

Defective release of growth hormone in parkinsonism improved by levodopa. N Engl J Med (1973) 0.78

Levodopa, involuntary movements and fusaric acid. JAMA (1971) 0.78

Tissue concentrations of manganese and adrenal function. Am J Physiol (1966) 0.78